相关实验视频
Updated: May 9, 2026
07:50
Isolation and Culture of Neonatal Mouse Cardiomyocytes
Published on: September 6, 2013
阿尔多斯特诱导了新生小鼠心脏细胞培养中的血管新生素转化酶基因表达
E Harada1, M Yoshimura, H Yasue
1Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Japan.
Circulation
|July 12, 2001
概括
阿尔多斯特会增加心脏细胞中的血管酶转化酶 (ACE) mRNA,而这种过程被螺旋诺拉克阻止. 这表明螺旋龙可能有助于控制心力衰竭的进展.
科学领域:
- 心血管研究研究心血管研究
- 分子心脏病学分子心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 心脏氨酸-血管氨酸-阿尔多斯特系统与心力衰竭的进展有关.
- 这个系统内的潜在的积极反循环可能会加剧疾病的严重程度.
研究的目的:
- 为了研究血管新素II或阿尔多素是否影响血管新素转化酶 (ACE) mRNA在心脏细胞中的表达.
- 探索心脏氨酸-血管氨酸-阿尔多斯特系统中潜在的积极反机制.
主要方法:
- 培养的新生儿鼠室内心脏细胞被用于研究基因表达.
- 实时逆转录-聚合酶连锁反应量化血管酶转化酶 (ACE) mRNA水平.
- 细胞被暴露在不同度和持续时间的血管新素II和阿尔多斯,有和没有螺旋.
主要成果:
- 阿尔多斯特 (10(-5) mol/L) 在心脏细胞中显著增加了ACE mRNA表达的23.3倍 (P<0.01).
- ангиотензин II 对 ACE mRNA 表达没有显著影响.
- 阿尔多斯特的效果依赖于时间和剂量,并被螺旋.
结论:
- 阿尔多斯特可以调节新生小鼠心脏细胞中的血管酶转化酶 (ACE) mRNA表达.
- 这种上调被螺旋龙抑制,这是一个矿物质皮质类受体对抗剂.
- 螺旋龙可以通过抵消阿尔多斯特和血管新生素II的作用来减轻心力衰竭的进展.
相关概念视频
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...